With more than 1,400 attendees from the United States and around the globe, the NCCN 16th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ was held at the Westin Diplomat in Hollywood, FL, March 9 – 13, 2011. The NCCN Annual Conference draws oncologists, oncology fellows, nurses, pharmacists, and many other health care professionals involved in the care of patients with cancer. This year's conference featured updates to selected NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) and new cancer therapies, discussion forums with experts from NCCN Member Institutions, and roundtable discussions featuring the foremost professionals from the academic, patient advocacy, government, payor, industry, and business realms of cancer care. In part 1 of our two-part special edition, we'll review conference events scheduled from Wednesday, March 9 through Thursday, March 10.
Please be on the lookout for part 2 of our two-part special edition on April 4, 2011, covering conference events scheduled from Friday, March 11 through Saturday, March 12.
Featured Articles
► NCCN Nursing Program Stresses a Multidisciplinary Approach to Cancer Care
On Wednesday, March 9, the 2011 NCCN Nursing Program: Role of the Advanced Practice Nurse in Quality Cancer Care™was hosted by the NCCN 16th Annual Conference in Hollywood, FL. The Nursing Program is designed to provide advanced practice oncology nurses with current and relevant information related to the management of cancer patients. Click here for more: NCCN Nursing Program Stresses a Multidisciplinary Approach to Cancer Care
► REMS, Biomarkers, and New Therapies Were Discussed by Pharmacists at the NCCN Annual Conference
On Wednesday, March 9, NCCN held the 2011 NCCN Pharmacy Program: Best Practices in Oncology Pharmacy Management™ directly before the NCCN 16th Annual Conference at the Westin Diplomat in Hollywood, FL. The Pharmacy Program provided pharmacists with insights regarding "best practices" on how other institutions are dealing with REMS, utilizing biomarkers, and incorporating new therapies into practice. Click here for more: REMS, Biomarkers, and New Therapies Were Discussed by Pharmacists at the NCCN Annual Conference
► NCCN Fellows Recognition Program Demonstrates the Promise of a New Generation of Oncologists
On Wednesday, March 9, NCCN conducted the 2011 NCCN Fellows Recognition Program: New Horizons in Quality Cancer Care™, with more than 200 fellows from around the country participating in the program. The program provides fellows with an opportunity to meet leading faculty from NCCN Member Institutions and to attend a series of lectures targeted specifically to specialists in training. Click here for more: NCCN Fellows Recognition Program Demonstrates the Promise of a New Generation of Oncologists
► NCCN Roundtable Addresses the Many Faces and Challenges of Caregivers
A roundtable dedicated to the challenges that caregivers confront highlighted the need for honest information and emotional support at the NCCN 16th Annual Conference. Sam Donaldson of ABC News moderated the moving discussion between notable caregivers ranging from spouses, mothers, daughters, and clinicians. Click here for more: NCCN Roundtable Addresses the Many Faces and Challenges of Caregivers
► 'The Coach and the Critic: Stories of Caregivers Where 'Kill Me' Is Not an Option'
Deputy Chief Medical Officer for the national office of the American Cancer Society, J. Leonard Lichtenfeld, MD, MACP, recalls his emotional reactions to the "The Many Faces and Challenges of Caregivers" roundtable discussion at the NCCN 16th Annual Conference. In "Dr. Len's Cancer Blog," Dr. Lichtenfeld recounts his touching experience of the stories from the panel of caregivers and their "frequently incredible accounts of the human spirit." Click here for more:
The Coach And The Critic: Stories Of Caregivers Where "Kill Me" Is Not An Option
► New Therapies for Metastatic Disease Addressed in Updated NCCN Guidelines for Breast Cancer
Highlighting important new treatment options for patients with breast cancer, Robert W. Carlson, MD, of Stanford Comprehensive Cancer Center, presented updates to the NCCN Guidelines for Breast Cancer at the NCCN 16th Annual Conference. Click here for more: New Therapies for Metastatic Disease Addressed in Updated NCCN Guidelines for Breast Cancer
► NCCN Reimbursement Resource Room Helps Mitigate Reimbursement Challenges
During the NCCN 16th Annual Conference on March 9 - 13, 2011, NCCN once again dedicated an area for clinicians to visit and learn about industry reimbursement assistance and services. Click here for more: NCCN Reimbursement Resource Room Helps Mitigate Reimbursement Challenges
► Jai Pausch Advises Caregivers to Balance Urgency for Care with Thoughtful Treatment Decisions in NCCN.com Column
Jai Pausch encourages caregivers to invest ample time developing a treatment plan for a loved one upon a cancer diagnosis, and offers strategies to address anxieties in her monthly column on NCCN.com. Click here for more: Jai Pausch Advises Caregivers to Balance Urgency for Care with Thoughtful Treatment Decisions in NCCN.com Column
Upcoming NCCN Live Events:
* NCCN Academy for Excellence & Leadership in Oncology™: School of Pharmaceutical & Biotech Business Enroll today for a two-day NCCN Academy for Excellence & Leadership in Oncology™ program being held Tuesday, July 12 through Wednesday, July 13, 2011 in Philadelphia, PA. Through this interactive program, pharmaceutical and biotech professionals will learn from key stakeholders what they view to be the most pressing issues in oncology today and how to apply this knowledge to create mutually successful working relationships. Click here to register: NCCN Academy for Excellence & Leadership in Oncology - Philadelphia
Updates: NCCN Guidelines™ and the NCCN Compendium™
NCCN Flash Update: NCCN Guidelines and Compendium Updated
Flash Update Sent December 8, 2010
NCCN Flash Update: NCCN Guidelines and Compendium Updated
NCCN has published updates to the NCCN Guidelines and the NCCN Drugs & Biologics Compendium (NCCN Compendium™) for Breast Cancer. These NCCN Guidelines are currently available as Version 2.2011.
* Denosumab was added to the Guidelines as an option for the prevention of skeletal-related events in patients with bone metastases with the following footnote: "Denosumab, zoledronic acid, or pamidronate (all with calcium and vitamin D supplementation) should be given (category 1) in addition to chemotherapy or endocrine therapy if bone metastasis present, expected survival 3 months or more, and renal function is adequate. Patients should undergo a dental examination with preventive dentistry prior to initiation of this therapy. The optimal schedule and duration of denosumab, zoledronic acid, or pamidronate are unknown."
* Eribulin was added to the list of preferred single agents for recurrent or metastatic breast cancer (category 2A).
* The discussion section has been updated to reflect the changes in the algorithm.
NCCN has published updates to the following chapter of the NCCN Compendium™ to reflect updates to the 2011
version of the corresponding NCCN Guidelines:
* Antiemesis
For the complete updated versions of the NCCN Guidelines and the NCCN Compendium™, please visit NCCN.org: NCCN - Evidence-Based Cancer Guidelines, Oncology Drug Compendium, Oncology Continuing Medical Education
Receive notification of updates to the NCCN Guidelines and NCCN Compendium as they happen
Subscribe to NCCN Flash Updates™ and have updates delivered straight to your inbox. NCCN Flash Updates™ is a subscription service from NCCN that provides timely access to updated and new information appearing in the NCCN Guidelines, the NCCN Compendium, and other NCCN Content. Subscribe now to NCCN Flash Updates™: https://subscriptions.nccn.org/login.aspx?
NCCN Member Institutions in the News
* Ohio State Performing Brain Surgery Through the Nose (The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute): Ohio State Performing Brain Surgery Through the Nose
* Vanderbilt-Ingram Cancer Center Launches Online Genetic Research Tool: Vanderbilt-Ingram Cancer Center Launches Online Genetic Research Tool
* The More Times a Woman Gives Birth, the Higher Her Risk of Rare But Aggressive 'Triple-Negative' Breast Cancer (Fred Hutchinson Cancer Research Center)
The More Times a Woman Gives Birth, the Higher Her Risk of Rare But Aggressive 'Triple-Negative' Breast Cancer
* Gene that Mediates Response to Key Cancer Drugs Frequently Mutated in Young Leukemia Patients Who Relapse (St. Jude Children's Research Hospital)
Gene that Mediates Response to Key Cancer Drugs Frequently Mutated in Young Leukemia Patients Who Relapse
Learn More about NCCN
About NCCN | NCCN Guidelines™ | NCCN Compendium™ | Educational Events | Publications | On-line Catalog
EDITORIAL TEAM:
Christine MacCracken, MSHEd, BSN, Director, Business Insights, Editor-in-Chief
Carrie Capili, Communications Specialist, Editor
Edward C. Li, PharmD, BCOP, Drugs and Biologics Editor
C. Lyn Fitzgerald, MJ, Vice President, U.S. & Global Development, Editor
Jill Mullen, MPA, Senior Manager, Corporate Communications & Policy, Editor
Megan Martin, Communications Manager
Kelly C. Simpson, Editor, eBulletin: International Edition
CONTRIBUTING WRITERS:
Kristina M. Gregory, RN, MSN, Vice President, Clinical Information Operations
Joan S. McClure, MS, Senior Vice President, Clinical Information & Publications
REMS, Biomarkers, and New Therapies Were Discussed by Pharmacists at the NCCN Annual Conference:
REMS, Biomarkers, and New Therapies Were Discussed by Pharmacists at the NCCN Annual Conference
No hay comentarios:
Publicar un comentario